Overview
Contract research firm's fiscal Q1 2026 revenue rose 0.8% yr/yr
Adjusted EBITDA for fiscal Q1 2026 missed analyst expectations
Company exited two leased facilities as part of site optimization plan
Outlook
Company did not provide specific guidance for future quarters or full year
Result Drivers
DSA REVENUE GROWTH - DSA segment revenue increased by 12% due to higher demand for discovery pharmacology and safety assessment services
RMS REVENUE DECLINE - RMS segment revenue decreased by 5.4%, primarily due to lower non-human primate volumes sold
OPERATING LOSS INCREASE - Operating loss increased due to higher costs in RMS segment despite some cost reductions
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Slight Miss* | $120.90 mln | $120.91 mln (2 Analysts) |
Q1 Net Income | -$28.40 mln | ||
Q1 Adjusted EBITDA | Miss | $1.80 mln | $7.61 mln (2 Analysts) |
Q1 Capex | $5.20 mln | ||
Q1 Operating Income | -$16.30 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Inotiv Inc is $2.75, about 557.4% above its February 6 closing price of $0.42
Press Release: ID:nGNX6nHM0x
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)